Full text
PDF![405](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e806/1977791/3fb6500567e4/brjcancer00060-0183.png)
![406](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e806/1977791/310f84db7157/brjcancer00060-0184.png)
![407](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e806/1977791/450c37a166b8/brjcancer00060-0185.png)
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bock S. N., Lee R. E., Fisher B., Rubin J. T., Schwartzentruber D. J., Wei J. P., Callender D. P., Yang J. C., Lotze M. T., Pizzo P. A. A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol. 1990 Jan;8(1):161–169. doi: 10.1200/JCO.1990.8.1.161. [DOI] [PubMed] [Google Scholar]
- Cortesina G., De Stefani A., Galeazzi E., Cavallo G. P., Jemma C., Giovarelli M., Vai S., Forni G. Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer. Head Neck. 1991 Mar-Apr;13(2):125–131. doi: 10.1002/hed.2880130208. [DOI] [PubMed] [Google Scholar]
- Cotran R. S., Pober J. S. Effects of cytokines on vascular endothelium: their role in vascular and immune injury. Kidney Int. 1989 Apr;35(4):969–975. doi: 10.1038/ki.1989.80. [DOI] [PubMed] [Google Scholar]
- Damle N. K., Doyle L. V., Bender J. R., Bradley E. C. Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol. 1987 Mar 15;138(6):1779–1785. [PubMed] [Google Scholar]
- Fleischmann J. D., Shingleton W. B., Gallagher C., Ratnoff O. D., Chahine A. Fibrinolysis, thrombocytopenia, and coagulation abnormalities complicating high-dose interleukin-2 immunotherapy. J Lab Clin Med. 1991 Jan;117(1):76–82. [PubMed] [Google Scholar]
- Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982 Jun 1;155(6):1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hardy J. R., Moore J., Lorentzos A., Ellis E., Jameson B., Gore M. E. Infectious complications of interleukin 2 therapy. Cytokine. 1990 Jul;2(4):311–311. doi: 10.1016/1043-4666(90)90034-q. [DOI] [PubMed] [Google Scholar]
- Henney C. S., Kuribayashi K., Kern D. E., Gillis S. Interleukin-2 augments natural killer cell activity. Nature. 1981 May 28;291(5813):335–338. doi: 10.1038/291335a0. [DOI] [PubMed] [Google Scholar]
- Lissoni P., Tancini G., Rovelli F., Cattaneo G., Archili C., Barni S. Serum interleukin-2 levels in relation to the neuroendocrine status in cancer patients. Br J Cancer. 1990 Nov;62(5):838–839. doi: 10.1038/bjc.1990.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Malkovský M., Loveland B., North M., Asherson G. L., Gao L., Ward P., Fiers W. Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature. 1987 Jan 15;325(6101):262–265. doi: 10.1038/325262a0. [DOI] [PubMed] [Google Scholar]
- Mavligit G. M., Zukiwski A. A., Gutterman J. U., Salem P., Charnsangavej C., Wallace S. Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases. J Clin Oncol. 1990 Feb;8(2):319–324. doi: 10.1200/JCO.1990.8.2.319. [DOI] [PubMed] [Google Scholar]
- Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
- Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M., Linehan W. M., Seipp C. A., White D. E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989 Oct;210(4):474–485. doi: 10.1097/00000658-198910000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Waldmann T. A., Goldman C. K., Robb R. J., Depper J. M., Leonard W. J., Sharrow S. O., Bongiovanni K. F., Korsmeyer S. J., Greene W. C. Expression of interleukin 2 receptors on activated human B cells. J Exp Med. 1984 Nov 1;160(5):1450–1466. doi: 10.1084/jem.160.5.1450. [DOI] [PMC free article] [PubMed] [Google Scholar]